Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital....

Descripción completa

Detalles Bibliográficos
Autores principales: Egaña, Larraitz, Auzmendi-Iriarte, Jaione, Andermatten, Joaquin, Villanua, Jorge, Ruiz, Irune, Elua-Pinin, Alejandro, Aldaz, Paula, Querejeta, Arrate, Sarasqueta, Cristina, Zubia, Felix, Matheu, Ander, Samprón, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595088/
https://www.ncbi.nlm.nih.gov/pubmed/33116181
http://dx.doi.org/10.1038/s41598-020-75477-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595088/
https://www.ncbi.nlm.nih.gov/pubmed/33116181
http://dx.doi.org/10.1038/s41598-020-75477-9

Ejemplares similares